Hercules Capital

Hercules Capital is excited to partner with Remodel Health, the #1 Individual Coverage Health Reimbursement Arrangement (ICHRA) provider for brokers. Remodel offers an end-to-end, white-labeled tech platform that supports employers and employees with everything they need to launch and access their ICHRA plans, including plan creation and administration, call center support, automated quoting, employee onboarding, HRIS integrations and payments with carriers and access to ancillary products. With this investment, Remodel will look to continue its national expansion. Learn more: https://lnkd.in/dXXD4DzB

In episode 35 of Ventured Growth, Behavox CEO Erkin Adylov shares with Hercules Capital's Catherine Jhung (she/her) how AI-enabled communications surveillance is protecting the financial services industry. Listen to the full episode, here: https://lnkd.in/eAFPixG6

A Senior Advisor in Lazard’s Global Healthcare Group, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode, he shares his thoughts on what makes a successful partnership or acquisition. Listen to the full episode with Hercules Capital's Janice Bourque, here: https://lnkd.in/egXdgN3F

Listen now -- a NEW episode of Ventured Growth! Episode 35: Revolutionizing Compliance – AI’s Role in Modern Finance featuring Erkin Adylov In this episode, Hercules Capital’s Catherine Jhung (she/her) speaks with Erkin Adylov, founder of Behavox and former hedge fund manager, about his career shift from managing investments to launching his own company. He explains why he started Behavox, which uses AI to help financial institutions stay compliant – a solution born from his firsthand experience seeing the limitations of traditional compliance methods. Subscribe on Apple, Spotify, Google, and other top podcast directories: https://lnkd.in/eAFPixG6

Hercules Capital has made a $120 million secured financing commitment to Omio, the world's leading travel platform for searching, comparing, and booking. "Omio has achieved significant milestones as it has scaled up its travel platform," said Steve Kuo, Senior Managing Director and Technology Group Head at Hercules Capital. "We are excited to partner with Omio and support its continued global expansion with a $120 million growth capital facility." Read more: https://lnkd.in/e-f5XWYA

As Hercules celebrates 20 years, our team is grateful for the opportunity to continue supporting groundbreaking and market-leading companies through critical growth milestones. We wish you and your loved ones a joyful Thanksgiving!

Hercules Capital's Life Sciences Team supports transformative companies driving advancements in biotechnology, pharmaceuticals, and healthcare services. We provide non-dilutive financing to expand clinical development, invest in R&D and early commercialization, acquire clinical assets, and extend cash runway through key value inflection points. With a focus on drug discovery, specialty pharma, healthcare services, medical devices, and more, we help life sciences innovators achieve critical milestones and unlock their full potential. Connect with us to learn more about the fit and timing of venture lending for your company: https://lnkd.in/dVjWaV6

Hercules Capital's Technology Team partners with innovative, venture-backed companies to fuel growth and navigate key milestones. From accelerating hiring to expanding into new markets, investing in transformative technologies, and strengthening balance sheets ahead of IPOs or acquisitions, we deliver timely, non-dilutive financing solutions. Our expertise spans enterprise software, cybersecurity, space, and defense technologies, business services, networking, AI, media and information services, and more, empowering technology leaders to achieve their boldest ambitions. Connect with us to learn more about the fit and timing of venture lending for your company: https://lnkd.in/eUWWwN4

Out today -- a NEW episode of Ventured Growth! Episode 34: The Evolution of Biotech Deals – From Pharma Consolidation to Innovation featuring Stephen Sands Stephen Sands is a Senior Advisor in Lazard’s Global Healthcare Group with a distinguished career in healthcare M&A. With over 35 years of experience, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode, Janice Bourque speaks with Stephen about his journey from bioengineer to healthcare M&A leader. They examine the forces that drive today’s major deals, from global expansion to complex valuation challenges, and the strategies that ensure success in a competitive market. Subscribe on Apple, Spotify, Google, and other top podcast directories: https://lnkd.in/egXdgN3F

Hercules Capital has made a new debt financing commitment to Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. "We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRONT-3 pivotal Phase 3 trial within our runway," said Marc Grasso M.D., Chief Financial Officer of Alector. "This credit facility provides additional funding to advance our preclinical pipeline including our proprietary, versatile Alector Brain Carrier blood-brain barrier platform and programs." "Hercules is pleased to enter into a strategic relationship with Alector as it advances its portfolio of assets aimed at treating neurodegenerative diseases," said Lake McGuire, Managing Director at Hercules Capital. "This capital commitment from Hercules seeks to help Alector deliver new therapeutic options to patients and further advance their novel and proprietary blood-brain barrier technology." Read more: https://lnkd.in/ewA_8_5c